cancer, immunology & cell death · mab to trail (human) (hs501) alx-804-300-c100 100 μg pab to...

International Edition

N E W S L E T T E RN E W S L E T T E RTOPIX 02/09

CANCER, IMMUNOLOGY & CELL DEATH

Apoptosis: Key Products & Standards 2-3

Tumor Markers 4

VEGF Receptor Inhibitors 4

Epigenetics – Chromatin Modification 5

Detection Sets & Kits 6-7

Biologically Active Compounds 8-9

Natural Products & Rare Antibiotics 10-11

Antibodies 12

NKT Cell Ligands 13

Ubiquitin Research – Linkage-specific Reagents 14

Tools for SUMO Research 15

New Organelle Profiling Tools 16

LATEST ADDITIONS

LATEST ADDITIONS

LATEST ADDITIONS

LATEST ADDITIONS

LATEST ADDITIONS

incorporating

www.enzolifesciences.com


2

TRAIL & TRAIL Receptors – The Widest Range!

Apoptosis: Key Products & Standards

KillerTRAIL™, Soluble (human) (rec.)[rhsTRAIL]

ALX-201-123-C500 BULK 500 μg SPECIFICITY: Binds to human and mouse TRAIL receptors and osteo-protegerin (OPG). APPLICATION: Induces apoptosis in a concentration range of 10-100ng/ml. NOTE: This protein does not require a cross-linker (enhancer) for its potent biological activity.

Monoclonal Antibodies to TRAIL Receptors

Antibodies to TRAIL

Product Name Product No. Format SizeMAb to TRAIL-R1 (human) (HS101) ALX-804-297-C100

ALX-804-297A-C100ALX-804-297F-T100

Purified (PF)PurifiedFITC

100 μg100 μg

100 testsMAb to TRAIL-R2 (human) (HS201) ALX-804-298-C100

ALX-804-298A-C100 ALX-804-298F-T100

Purified (PF)PurifiedFITC

100 μg100 μg

100 testsMAb to TRAIL-R3 (human) (HS301) ALX-804-344A-C100 100 μgMAb to TRAIL-R3 (human) (LEIA) ALX-804-136-C100 100 μgMAb to TRAIL-R4 (human) (HS402) ALX-804-299A-C100 100 μgMAb to DcTRAIL-R2 (mouse) (Lucy-1) ALX-804-817-C100 100 μg

Product Name Product No. SizeKillerTRAIL™, Soluble (human) (rec.) ALX-201-073-C020

ALX-201-073-3020 SuperPackTM20 μg

3 x 20 μgSuperKillerTRAIL™, Soluble (human) (rec.) ALX-201-115-C010


3 x 10 μgSuperKillerTRAIL™, Soluble (mouse) (rec.) ALX-201-130-C020


3 x 20 μgTRAIL, Soluble (human) (rec.) ALX-522-003-C010


3 x 10 μgTRAIL, Soluble (human) (rec.) Set ALX-850-018-KI01 1 SetTRAIL Receptor-1 to -4 Set ALX-850-062-KI02 1 Set

Product Name Product No. SizeMAb to TRAIL (human) (VI10E) ALX-804-325-C100 100 μgMAb to TRAIL (human) (III6F) ALX-804-326-C100 100 μgMAb to TRAIL (human) (2E5) ALX-804-296-C100 100 μgMAb to TRAIL (human) (HS501) ALX-804-300-C100 100 μgPAb to TRAIL (human) ALX-210-732-R100 100 μl

Recombinant Proteins

Many citations! For a comprehensive bibliography please visit our website.

AP

OP

TOSI

S: K

EY P

RO

DU

CTS

& S

TAN

DA

RD

S

FIGURE: Specificity of Killer TRAIL™-induced apoptosis. Concentration dependent blocking of apoptosis induction of BJAB cells with anti-TRAIL MAb 2E5 (Prod. No. ALX-804-296) reveals specificity of Killer TRAIL™-mediated killing.

incorporating

Purified (PF) = Purified (Preservative free); FC = Flow Cytometry; ICC = Immunocytochemistry; IP = Immunoprecipitation; IHC = Immunohistochemistry (FS = Frozen Sections, PS = Paraffin Sections); WB = Western blot; BP = Blocking Peptide


3

FasL [APO-1L; CD95L; CD178] – The Reliable Source™

FasL, Soluble (human) (rec.)ALX-522-001-C010 10 μgALX-522-001-3010 SuperPack™ 3 x 10 μgProduced in HEK 293 cells. The extracellular domain of human FasL (APO-1L; CD95L; CD178) (aa 103-281) is fused at the N-terminus to a linker peptide (26 aa) and a FLAG®-tag. Glycosylation of rhsFasL is similar to natural hu-man FasL. SPECIFICITY: Binds to human, mouse and rat Fas (CD95; APO-1). BIOLOGICAL ACTIVITY: Kills Fas-sensitive cells at concentrations of >50ng/ml. Cross-linking enhancer (see Set Prod. No. ALX-850-014) increases the activity of rhsFasL approximately 50-fold. ATTENTION: Results using sFasL may differ from those obtained with agonistic antibodies!

SuperFasLigand™, Soluble (human) (rec.)ALX-522-020-C005 5 μgALX-522-020-3005 SuperPack™ 3 x 5 μgProduced in HEK 293 cells. The extracellular domain of human FasL (APO-1L; CD95L; CD178) (aa 103-281) is fused at the N-terminus to a linker peptide (26 aa) and a FLAG®-tag. Glycosylation of rhsSuperFasLigand™ is similar to natural human FasL. SPECIFICITY: Binds to human, mouse and rat Fas (CD95; APO-1). BIOLOGICAL ACTIVITY: Kills Fas-sensitive cells at concentrations of >1ng/ml. NOTE: Does not require enhancer.

The Standard Apoptosis Inducer

MAb to Fas [CD95] (human) (APO-1-3)ALX-805-020-C100 100 μgCLONE: APO-1-3. ISOTYPE: Mouse IgG3. IMMUNOGEN: Human Fas (CD95; APO-1). SPECIFICITY: Recognizes human Fas. APPLICATION: FC, IP, WB, FUNC (induces apoptosis – no cross-linking required).LIT: Monoclonal antibody-mediated tumor regression by induction of apoptosis: B.C. Trauth, et al.; Science 245, 301 (1989) For a comprehensive bibliography please visit our website.

Key Antibodies to FLIP

MAb to FLIP (human) (NF6)ALX-804-428-C050 50 μgALX-804-428-C100 100 μgCLONE: NF6. ISOTYPE: Mouse IgG1. IMMUNOGEN: Recombinant human FLIP (aa 1-194) fusion protein. SPECIFICITY: Recognizes short (FLIPS) and long (FLIPL) splice variants of human FLIP. APPLICATION: WB.LIT: The role of c-FLIP in modulation of CD95-induced apoptosis: S. Scaffidi, et al.; J. Biol. Chem. 274, 1541 (1999) For a comprehensive bibliography please visit our website.

MAb to FLIP (Dave-2)ALX-804-127-C100 100 μgCLONE: Dave-2. ISOTYPE: Rat IgG2a. IMMUNOGEN: Recombinant hu-man FLIP (aa 1-480). SPECIFICITY: Recognizes an epitope (aa 1-200) present in both short (FLIPS) and long (FLIPL) splice variants of human and mouse FLIP. APPLICATION: IP, WB.LIT: Fas engagement induces the maturation of dendritic cells (DCs), the release of in-terleukin (IL)-1beta, and the production of interferon gamma in the absence of IL-12 during DC-T cell cognate interaction: a new role for Fas ligand in inf: M. Rescigno, et al.; J. Exp. Med. 192, 1661 (2000) For a comprehensive bibliography please visit our website.

Key Antibodies to Caspase-8

MAb to Caspase-8 (human) (C15)ALX-804-429-C050 50 μgALX-804-429-C100 100 μgCLONE: C15. ISOTYPE: Mouse IgG2b. IMMUNOGEN: Recombinant human caspase-8 (aa 181-478). SPECIFICITY: Recognizes the p18 subunit of human caspase-8. APPLICATION: ICC, IP, WB.LIT: FLICE is predominantly expressed as two functionally active isoforms, caspase-8/a and caspase-8/b: C. Scaffidi, et al.; J. Biol. Chem. 272, 26953 (1997) For a compre-hensive bibliography please visit our website.

MAb to Caspase-8 (human) (12F5)ALX-804-242-C100 100 μgCLONE: 12F5. ISOTYPE: Mouse IgG2b. IMMUNOGEN: Recombinant hu-man caspase-8. SPECIFICITY: Recognizes human procaspase-8 and active human caspase-8. Detects procaspase-8 (p55/54), the inter-mediate cleavage products (p43/41) and the p18 active subunit of caspase-8 by Western blot. Does not recognize mouse caspase-8. AP-PLICATION: IP, WB.LIT: Differential regulation and ATP requirement for caspase-8 and caspase-3 activation during CD95- and anticancer drug-induced apoptosis: D. Ferrari, et al.; J. Exp. Med. 188, 979 (1998) For a comprehensive bibliography please visit our website.

The Gold Standards!

FasL, Soluble (human) (rec.) SetALX-850-014-KI02 1 SetSPECIFIC ACTIVITY: ED50: 1ng/ml (A20 cells). BIOLOGICAL ACTIVITY: Kills Fas-sensitive cells at concentrations of >1ng/ml in the presence of cross-linking enhancer. SET CONTAINS:

10μg rec. human soluble Fas ligand (Prod. No. ALX-522-001)• 4x50μg of enhancer for ligands (Prod. No. ALX-804-034) which in-• creases the biological activity (induction of apoptosis) by approx. 50-fold to a concentration range of 1-5ng/ml.

HIGHLIGHTTNC:TWEAK – Superior Affinity

Some TNF ligands (such as TWEAK (mouse) or FasL (mouse)) produced as soluble forms do not assemble into stable trim-ers and show low receptor binding. Addition of the tenascin-C oligomerization domain (TNC) (from chicken) at the N-termi-nus of recombinant mouse soluble TWEAK stabilizes the TNF homology domain (THD) of rmsTWEAK into a trimer and in-creases binding to its respective TNF receptor.

LIT: Enforced covalent trimerization increases the activity of the TNF ligand family members TRAIL and CD95L: D. Berg, et al.; Cell Death Differ. 14, 2021 (2007)

TNC:TWEAK, Soluble (mouse) (rec.)ALX-522-138-C010 10 μg

AP

OP

TOSI

S: K

EY P

RO

DU

CTS

& S

TAN

DA

RD

S


4

Tumor Markers

VEGF Receptor Inhibitors

Folate Receptor α

The folate receptor is a highly selective tumor marker overex-pressed in greater than 90% of ovarian carcinomas.

MAb to Folate Receptor α (Mov18/ZEL)ALX-804-439-R100 100 μlCLONE: Mov18/ZEL. ISOTYPE: Mouse IgG1. IMMUNOGEN: Membrane prepara-tion from a human ovarian carcinoma specimen. SPECIFICITY: Recognizes membrane-bound and soluble human and monkey folate receptor (FR) α. Does not cross-react with mouse or rat folate receptor. Does not cross-react with the β-isoform. APPLICATION: FC, ICC, IHC (FS), IP, WB.LIT: Characterization of human ovarian carcinoma-associated antigens defined by novel mono-clonal antibodies with tumor-restricted specificity: S. Miotti, et al.; Int. J. Cancer 39, 297 (1987) For a comprehensive bibliography please visit our website.

c-erbB-2 – The Standard Breast Cancer Marker

Overexpression of c-erbB-2 has been associated with resist-ance to chemotherapy and poor survival in several human tumors.

MAb to c-erbB-2 (human) (MGR2)ALX-804-573-C100 100 μgCLONE: MGR2. ISOTYPE: Mouse IgG1. IMMUNOGEN: CaLu 3 lung carcinoma cell line. SPECIFICITY: Recognizes an epitope present in the extracellular domain of human c-erbB-2 (HER-2; neu). APPLICATION: FC, IHC (FS), IP. LIT: Selection of monoclonal antibodies which induce internalization and phosphorylation of p185HER2 and growth inhibition of cells with HER2/NEU gene amplification: E. Tagliabue, et al.; Int. J. Cancer 47, 933 (1991) p185 HER2/neu epitope mapping with murine monoclonal anti-bodies: F. Centis, et al.; Hybridoma 11, 267 (1992)

globo H

The MAb MBr1 recognizes a saccharidic epitope (CaMBr1) overexpressed on a high percentage of human breast, ovary, lung and prostate carcinomas which is associated with tumor aggressiveness and survival outcome.

MAb to globo H (MBr1)ALX-804-550-C050 50 μgCLONE: MBr1. ISOTYPE: Mouse IgM. IMMUNOGEN: Membrane preparation from the human breast carcinoma cell line MCF7. SPECIFICITY: Recognizes hu-man, rat, dog and cat membrane bound glycoconjugates (glycoproteins, mucins and glycolipids) expressing the globo H or its tetrasaccharide ter-minus. Does not cross-react with mouse. APPLICATION: FC, ICC, IHC (FS, PS), WB (for glycoproteins).LIT: Generation of monoclonal antibodies reacting with normal and cancer cells of human breast: S. Menard, et al.; Cancer Res. 43, 1295 (1983)

FIGURE: Immunoperoxidase staining with anti-Folate Receptor α (Prod. No. ALX-804-439) of acetone-fixed cryostatic sections from a human serous ovary carcinoma show-ing membrane localization.

Tumor cells secrete chemokines and growth factors that induce the pro-liferation of microvascular endothelial cells. Vascular endothelial growth factor (VEGF) is one of the multifunctional cytokines that bind to extracel-lular domains of at least three different receptor kinases (VEGF receptor [VEGFR]; VEGFR1-VEGFR3) and neurophilins involved in anti-apoptotic sig-naling, mitosis, and cell taxis. Thus, VEGF is a key target of anti-angiogenic interventions.

AAL-993BML-EI367-0005 5 mgBML-EI367-0025 25 mgHighly potent inhibitor of VEGFR-1 (IC50=130nM), VEGFR-2 (IC50=23nM) and VEGFR-3 (IC50=18nM). At higher concentrations it inhibits PDGFR-β (640nM), c-Kit (236nM) and CSF-1R (380nM).

SU4312BML-EI306-0005 5 mgBML-EI306-0025 25 mgPotent and selective inhibitor of VEGFR-2 (Flk-1, KDR). It displays a 100-fold greater potency for the unactivated form of the kinase (Ki=0.04μM) com-pared to the activated form (Ki=4μM).

PKC-412BML-EI370-0001 1 mgBML-EI370-0005 5 mgOriginally identified as a PKC inhibitor, PKC-412 has been shown to inhibit a broad spectrum of kinases including KDR, VEGFR, PDGFR, c-kit and other receptor tyrosine kinases. It is a potent inhibitor of mutant Flt-3 - including mutant forms found in acute myeloid leukemia - in vitro and in vivo. It was shown to abrogate tumor angiogenesis in vivo.

ZM-306416BML-EI353-0001 1 mgBML-EI353-0010 10 mgVEGF receptor tyrosine kinase inhibitor. Inhibits KDR (IC50=100nM) and Flt (IC50=2μM) tyrosine kinases.

VEG

F R

ECEP

TOR

IN

HIB

ITO

RS

TUM

OR

MA

RK

ERS

incorporating



5

Epigenetics – Chromatin Modifi cation

Antibody HighlightsMAb to Histone H3 (K9 methylated) (6F12-H4)ALX-804-673-C050 50 μgCLONE: 6F12-H4. ISOTYPE: Mouse IgG1. IMMUNOGEN: Branched pep-tide of the sequence (QTARK(Me)3STGGKA)2-KC. SPECIFICITY: Rec-ognizes human and mouse K9-trimethylated histone H3. Cross-re-acts with K9 di- and weakly with K9 monomethylated histone H3. Does not cross-react with unmethylated histone H3. APPLICATION: ELISA, ICC, IP, WB.

FIGURE: Immunocytochemistry of irradiated mouse embryonic fibroblasts (iMEFs) stained with DAPI and MAb to Histone H3 (K9 methylated) (6F12-H4) (Prod. No. ALX-804-673). Figure courtesy of Susanne Opravil and Thomas Jenuwein, Institute of Molecular Pathology (IMP) Vienna, Austria.

PAb to Dimethyl-lysineBML-SA667-0100 100 μlFrom rabbit. IMMUNOGEN: Dimethylated bovine serum albumin. SPE-CIFICITY: Recognizes dimethyl-lysine; species independent. APPLI-CATION: WB.

PAb to Dimethyl-lysine (Affinity Purified)BML-SA668-0050 50 μgFrom rabbit. IMMUNOGEN: Dimethylated KLH. SPECIFICITY: Recognizes proteins containing dimethylated lysine residues in SDS-PAGE im-munoblots. Does not cross-react with monomethylated or trimeth-ylated lysines in peptides. APPLICATION: WB.

HDAC/Sirtuin KitsHDAC1 Fluorimetric Drug Discovery KitBML-AK511-0001 1 Kit

Fluor de Lys™• system (Fluorogenic Histone Deacety-lase Lysyl Substrate/Developer).

Highly sensitive and convenient. No Radioactivity.•

Simple two step assay procedure.•

HTS Friendly-Mix and Read on One 96-well Plate.•

Other Fluor de Lys™ system HDAC Kits:

HDAC Fluorimetric Activity Assay KitBML-AK500-0001 1 Kit

HDAC Fluorimetric Cellular Activity Assay KitBML-AK503-0001 1 Kit

SIRT1 Fluorimetric Activity Assay/Drug Discovery KitBML-AK555-0001 1 Kit

Lysine-specific Histone Demethylase 1 [LSD1]

LSD1 (lysine-specifi c histone demethylase 1) catalyzes the oxidative demethylation of mono- and dimethylated H3K4. H3K4 methylation is considered a transcription activating chromatin mark and in vivo LSD1 is frequently found in asso-ciation with the transcriptional corepressor protein CoREST and HDACs 1 or 2. LSD1 is inhibited by a number of estab-lished monoamine oxidase inhibitor drugs. That and the fact that its expression is elevated in a number of cancers may make it a promising target for drug development.

LSD1 (human) (rec.)BML-SE544-0050 50 μgProduced in E. coli. Human LSD1 (aa 151-852). Highly active in a peroxi-dase-coupled assay with the Histone H3 Dimethyl Lysine-4 Peptide (Prod. No. BML-P256).

Inhibitor:

TranylcypromineBML-EI217-0001 1 gBML-EI217-0005 5 gInhibits BHC110/LSD1 (IC50=2μM).

EPIG

ENET

ICS

– CH

RO

MAT

IN M

OD

IFIC

ATIO

N


6

Detection Sets & Kits

Netrin-1 – A Multifunctional Survival FactorNetrin-1 is involved in neurobiology, leukocyte migration, cell adhesion and angiogenesis. To carry its functions, netrin-1 interacts with specifi c receptors (DCC/neogenin, UNC5 and DSCAM) that belong to the family of dependence receptors. These receptors induce apoptosis in the absence of their respective ligand, and promote survival when bound to their lig-and. As a survival factor, netrin-1 contributes to the control of tumorigen-esis. Netrin-1 is overexpressed in metastatic breast cancer, conferring a selective advantage for tumor cell survival.

Netrin-1 (human) Detection SetAPO-54N-044-KI01 1 SetFor the quantitative determination of human netrin-1 from biological fluids (serum and cell culture supernatant). SENSITIVITY: 1ng/ml (range 2 to 128ng/ml). QUANTITY: For 5x96 wells.

BAFF Detection – Highest Sensitivity on the MarketBAFF (BLyS; TALL1) is a cytokine expressed predominantly by cells of the immune system such as neutrophils, monocytes, macrophages, dendritic cells, follicular dendritic cells, activated T cells and some malignant B cells. BAFF is a master regulator of peripheral B cell survival, and also acts in processes such as immunoglobulin isotype switch and B cell co-stimulation. Besides its major role in B cell biology, BAFF co-stimulates activated T cells. In humans, elevated levels of soluble BAFF have been detected in the serum of patients with various autoimmune diseases.

BAFF, Soluble (human) Detection Set (High Sensitivity) APO-54N-046-KI01 1 SetFor the quantitative determination of human BAFF in biological fluids (serum, plasma and cell culture supernatant). SENSITIVITY: 5pg/ml (range 7.8 to 500pg/ml). QUANTITY: For 5x96 wells.

RIG-I – Cytoplasmic Sensor for Antiviral DefenseViral infection of mammalian cells leads to an innate immune response by which type I interferons (IFNs) are activated to limit viral replication. Antiviral signaling pathways are initiated upon detection of viral nucleic acids by pattern recognition receptors (PRRs). One example for such a PRR is the retinoic acid inducible gene-1 (RIG-I), which functions as RNA sensor in the cytosol.

RIG-I (human) (IntraCellular) ELISA KitAPO-54N-045-KI01 1 KitFor the quantitative determination of human RIG-I in cell extracts. SENSITIVITY: 0.1ng/ml (range 0.156 to 10ng/ml). QUANTIT Y: For 96 wells (~80 tests).

DET

ECTI

ON

SET

S &

KIT

S

incorporating



TEX

T

7

Latest Additions

MMP Drug Discovery KitsThe MMPs are a family of zinc-containing endopepti-dases that degrade various components of the extra-cellular matrix (ECM). Several MMPs have been strong-ly implicated in multiple stages of cancer progression including the acquisition of invasive and metastatic properties. Enzo Life Sciences offers a wide range of QuantiZymeTM Assay Systems, designed to screen MMP inhibitors.

Matrix Metalloproteinase-2 (MMP-2) Colorimetric Drug Discovery KitBML-AK408-0001 1 Kit

Matrix Metalloproteinase-2 (MMP-2) Fluorimetric Drug Discovery KitBML-AK409-0001 1 Kit

Matrix Metalloproteinase-9 (MMP-9) Colorimetric Drug Discovery KitBML-AK410-0001 1 Kit

Matrix Metalloproteinase-9 (MMP-9) Fluorimetric Drug Discovery KitBML-AK411-0001 1 Kit

Cathepsin K Drug Discovery KitCathepsin K, a cysteine protease produced by osteoclasts, plays a key role in osteoclast-mediated bone degradation. In addition, cathepsin K is also produced by cancer cells that metastasize to bone where it functions in proteolytic pathways that promote cancer cell invasion.

Cathepsin K Drug Discovery KitBML-AK430-0001 1 KitComplete assay system designed to screen inhibitors of cathepsin K. Using a convenient microplate format, cathepsin K activity is monitored fluorimetrically using the substrate provided in the kit. QUANTITY: 96 assays.

TRAIL-OPG Complex Kit Osteoprotegerin (OPG) is a secreted member of the TNF (tumor necrosis factor) receptor superfamily. Its expres-sion targets the skeletal, immune, and vascular systems. OPG protects the skeleton from excessive bone resorp-tion by acting as a decoy receptor for RANKL. OPG also functions as a soluble receptor for the TNF ligand TRAIL preventing it to activate apoptotic signaling cascade and therefore providing cancer cells with a survival advan-tage. TRAIL-OPG levels have been reported to be as-sociated with different diseases such as autoimmune arthritis, diabetic nephropathy and atherosclerosis.

TRAIL-Osteoprotegerin (human) ELISA KitAPO-54N-041-KI01 1 KitFor the quantitative determination of human TRAIL complexed to OPG in biological fluids (serum, plasma and cell culture supernatant). SEN-SITIVITY: 200pg/ml (range 0.25 to 16ng/ml). QUANTITY: For 96 wells (~80 tests).

Free Osteoprotegerin (human) ELISA KitAPO-54N-042-KI01 1 KitFor the quantitative determination of free human OPG (not complexed to RANKL or TRAIL) in biological fluids (serum, plasma and cell culture supernatant). SENSITIVITY: 20pg/ml (range 0.031 to 2ng/ml). QUAN-TITY: For 96 wells (~80 tests).

FIGURE: Standard Curve for APO-54N-041-K101

DET

ECTI

ON

SET

S &

KIT

S


8

Hedgehog Pathway Blocker

Cyclopamine [11-Deoxyjervine]

ALX-430-159-M001 1 mgALX-430-159-M005 5 mgBlocks activation of the Hedgehog (Hh) response pathway. Disrupts choles-terol biosynthesis. Displays anti-tumor properties. Induces apoptosis.LIT: The teratogenic Veratrum alkaloid cyclopamine inhibits sonic hedgehog signal transduction: J.P. Incardona, et al.; Development 125, 3553 (1998) Pancreas development is promoted by cy-clopamine, a hedgehog signaling inhibitor: S.K. Kim & D.A. Melton; PNAS 95, 13036 (1998) For a comprehensive bibliography please visit our website.

Potent nAChR Subtypes Ligand

CytisineALX-350-373-M005 5 mgALX-350-373-M025 25 mgNicotine agonist. Potent ligand for many nAChR subtypes. Shows analgesic, antihypertensive and inotropic activities.LIT: Some studies on cytisine and its methylated derivatives: R.B. Barlow & L.J. McLeod; Br. J. Pharmacol. 35, 161 (1969) For a comprehensive bibliography please visit our website.

Analog of Taxol

Docetaxel[Taxotere]

BML-T129-0005 5 mgBML-T129-0025 25 mgBML-T129-0250 250 mgTaxane-type antineoplastic agent structurally similar to taxol. It reversibly binds to polymerized tubulin inhibiting depolymerization. Induces apoptosis. Tumor cells rapidly develop resistance to docetaxel via various mechanisms.LIT: Docetaxel in the management of prostate cancer: current standard of care and future direc-tions: S. De Dosso and D.R. Berthold; Expert Opin. Pharmacother. 9, 1969 (2008) Mitotic catas-trophe and apoptosis induced by docetaxel in hormone-refractory prostate cancer cells: F. Fabbri, et al.; J. Cell. Physiol. 217, 494 (2008)

Potent CDK Inhibitor

Flavopiridol[Alvocidib]

ALX-430-161-M005 5 mgALX-430-161-M025 25 mgPotent inhibitor of cyclin-dependent kinases (CDKs). Induces apoptosis in certain tumor cells. Interacts with multidrug resistance protein 1 (MRP1).LIT: Structural basis for specificity and potency of a flavonoid inhibitor of human CDK2, a cell cy-cle kinase: W.F. Jr. De Azevedo, et al.; PNAS 93, 2735 (1996) Flavopiridol induces G1 arrest with inhibition of cyclin-dependent kinase (CDK) 2 and CDK4 in human breast carcinoma cells: B.A. Carlson, et al.; Cancer Res. 56, 2973 (1996) For a comprehensive bibliography please visit our website.

Potent Cytotoxic Compound

Gemcitabine . HCl[2’-Deoxy-2’,2’-difluorocytidine . HCl]

ALX-480-101-M025 25 mgALX-480-101-M100 100 mgCytotoxic. Induces apoptosis. Inhibits DNA synthesis.LIT: Cellular elimination of 2’,2’-difluorodeoxycytidine 5’-triphosphate: a mechanism of self-poten-tiation: V. Heinemann, et al.; Cancer Res. 52, 533 (1992) Gemcitabine: a cytidine analogue ac-tive against solid tumors: Y.F. Hui & J. Reitz; Am. J. Health Syst. Pharm. 54, 162 (1997) Cellular pharmacology of gemcitabine: E. Mini, et al.; Ann. Oncol. 17, v7 (2006).

ROS-mediated Apoptosis Inducer

HispolonALX-350-384-M005 5 mgALX-350-384-M025 25 mgInduces ROS-mediated apoptosis. Antiviral.LIT: Inhibition of chemiluminescence response of human mononuclear cells and suppression of mitogen-induced proliferation of spleen lymphocytes of mice by hispolon and hispidin: N.A. Ali, et al.; Pharmazie 51, 667 (1996) Hispolon induces apoptosis in human gastric cancer cells through a ROS-mediated mitochondrial pathway: W. Chen, et al.; Free Radic. Biol. Med. 45, 60 (2008).

Biologically Active Compounds

O

NH

CH3

CH3

H H

H

OH

CH3 H

HCH3

Cyclopamine

Cytisine

Docetaxel

Flavopiridol Gemcitabine . HCl

Hispolon

BIO

LOG

ICA

LLY

ACT

IVE

COM

PO

UN

DS

incorporating



9

Latest AdditionsVoltage-gated Sodium Channel Blocker

LamotrigineALX-430-160-M025 25 mgALX-430-160-M100 100 mgALX-430-160-M500 500 mgBlocks voltage-gated sodium channels. Inhibits the release of glutamate. Neuroprotective. Anticonvulsant.LIT: Lamotrigine (BW430C), a potential anticonvulsant. Effects on the central nervous system in comparison with phenytoin and diazepam: A.F. Cohen, et al.; Br. J. Clin. Pharmacol. 20, 619 (1985) For a comprehensive bibliography please visit our website.

Selective Apoptosis Inhibitor

Mdivi-1BML-CM127-0010 10 mgBML-CM127-0050 50 mgMdivi-1 is a selective inhibitor of mitochondrial division. Inhibits apoptosis by inhibiting mitochondrial outer membrane permeabilization. Inhibits Dnm1 GTPase but is not a general inhibitor of GTPases.LIT: Chemical inhibition of the mitochondrial division dynamin reveals its role in Bax/Bak-depend-ent mitochondrial outer membrane permeabilization: A. Cassidy-Stone, et al.; Dev. Cell 14, 193 (2008)

Pan Bcl-2-Family Inhibitor

Obatoclax[GX15-070]

ALX-430-162-M001 1 mgBcl-2 inhibitor. Antagonizes MCL-1 and overcomes MCL-1-mediated resist-ance to apoptosis.LIT: Bcl-2 inhibitors induce apoptosis in chronic lymphocytic leukemia cells: C. Campas, et al.; Exp. Hematol. 34, 1663 (2006) Small molecule obatoclax (GX15-070) antagonizes MCL-1 and overcomes MCL-1-mediated resistance to apoptosis: M. Nguyen, et al.; PNAS 104, 19512 (2007) For a comprehensive bibliography please visit our website.

Cell Permeable Resveratrol Analog

PterostilbeneALX-385-034-M025 25 mgALX-385-034-M100 100 mgALX-385-034-M500 500 mgAntioxidant, antiproliferative, anti-inflammatory, anti-hyperglycemic and anti-diabetic agent. Induces apoptosis. Inhibits activator protein 1 (AP-1) and NF-κB activation. Moderately inhibits COX-1 and COX-2.LIT: Antihyperglycemic activity of phenolics from Pterocarpus marsupium: M Manickam, et al.; J. Nat. Prod. 60, 609 (1997) Cancer chemopreventive and antioxidant activities of pterostilbene, a naturally occurring analogue of resveratrol: A.M. Rimando, et al.; J. Agric. Food Chem. 50, 3453 (2002) For a comprehensive bibliography please visit our website.

Potent GABAAR Antagonist

ThiocolchicosideALX-350-374-M001 1 mgALX-350-374-M005 5 mgALX-350-374-M025 25 mgPotent competitive antagonist of GABAAR function. Muscle relaxant. Anti-inflammatory. Analgesic. Shows strong epileptogenic and convulsant activity.LIT: Review of the toxicology, pharmacodynamics and pharmacokineticss of thiocolchicoside, a GABA-agonist muscle relaxant with anti-inflammatory and analgesic actions: J.M. Janbroers; Acta Ther. 13, 221 (1987) For a comprehensive bibliography please visit our website.

Lipophilic ACE Inhibitor

Trandolapril[RU-44570]

ALX-270-493-M010 10 mgALX-270-493-M050 50 mgAngiotensin-converting enzyme (ACE) inhibitor with long biological half-life and a high degree of lipophilicity.LIT: Angiotensin-converting enzyme inhibition, anti-hypertensive activity and hemodynamic profile of trandolapril (RU 44570): N.L. Brown, et al.; Eur. J. Pharmacol. 148, 79 (1988) For a compre-hensive bibliography please visit our website.

Lamotrigine

Mdivi-1

Obatoclax

Pterostilbene

Thiocolchicoside

N

O

NH

CH3

OH

O

OO CH3

H

HN

O

NH

CH3

OH

O

OO CH3

H

H

Trandolapril

BIO

LOG

ICA

LLY

ACT

IVE

COM

PO

UN

DS


10

Just Released

PyrrolcarbonyltalosideALX-380-134-M001 1 mgALX-380-134-M005 5 mgIsolated from Kitasatospora sp. (Gö M1). Shows weak cytotoxic activity against different tumor cell lines. Has antiparasitic activity.LIT: 6-Deoxy-a-L-talopyranosids from Streptomyces sp.: J. Bitzer & A. Zeeck; Eur. J. Org. Chem. 2006, 3661

GenipinALX-350-383-M025 25 mgALX-350-383-M100 100 mgIsolated from Gardenia jasminoides Ellis. Cell permeable inhibitor of un-coupling protein 2 (UCP2). Increases glucose-stimulated insulin secre-tion, mitochondrial membrane potential and ATP levels in pancreatic island cells. Induces apoptosis. Protein cross-linking agent. Anti-inflammatory and anti-angiogenic.LIT: Genipin-induced apoptosis in hepatoma cells is mediated by reactive oxygen species/c-Jun NH2-terminal kinase-dependent activation of mitochondrial pathway: B.C. Kim, et al.; Biochem. Pharmacol. 70, 1398 (2005)

Natural Products & Rare Antibiotics

Pyrrolcarbonyltaloside

Genipin

Product Activity Prod. No. Size

Acetomycin Anti-bacterial, Anti-fungalCytotoxic

ALX-380-137-M001ALX-380-137-M005

1 mg5 mg

Asperloxine A Anti-inflammatory ALX-380-126-M001 1 mg

Aspinonene Related to Aspyrone (Prod. No. ALX-380-121)

ALX-380-132-M001ALX-380-132-M005

1 mg5 mg

Aureothin[Mycolutein; Distacin]

Oxidoreductase inhibitor ALX-380-140-M001ALX-380-140-M005

1 mg5 mg

Curvulin PhytotoxinMicrotubule assembly inhibitor

ALX-350-164-M001ALX-350-164-M005

1 mg5 mg

Curvularin iNOS (NOS II) inhibitorCell division inhibitor

ALX-380-305-M001ALX-380-305-M005

1 mg5 mg

Cycloaspeptide A Anti-malarial ALX-350-385-M001ALX-350-385-M005

1 mg5 mg

Elmycin B Anti-bacterial, Cytotoxic ALX-380-139-M001ALX-380-139-M005

1 mg5 mg

Finasteride[MK-906]

5α-Reductase inhibitor ALX-270-491-M100ALX-270-491-M500

100 mg500 mg

Fulvic acid — ALX-350-386-M001ALX-350-386-M005

1 mg5 mg

Iromycin A eNOS (NOS III) inhibitorThaxtomine biosynthesis inhibitor

ALX-380-124-MC05ALX-380-124-M001ALX-380-124-M005

0.5 mg1 mg5 mg

Isofusidienol A Anti-fungal, Anti-bacterial ALX-380-130-M001ALX-380-130-M005

1 mg5 mg

Luisol A — ALX-380-135-M001ALX-380-135-M005

1 mg5 mg

NAT

UR

AL

PR

OD

UCT

S &

RA

RE

AN

TIB

IOTI

CS

incorporating



11

Latest AdditionsPotent P-glycoprotein Inhibitors

Sipholenone A and Sipholenol A are isolated from marine sponge Callyspongia siphonella formerly known as Sipho-nochalina siphonella. They effi ciently inhibit the function of P-glycoprotein (Pgp). New reversing agents for treatment of multidrug resistance (MDR) in Pgp-overexpressing tumors. Antiproliferative activity. Cytotoxic.

Sipholenone AALX-350-381-C100 100 μg

Sipholenol AALX-350-358-C100 100 μgLIT: The Sipholanes: A novel group of triterpenes from the marine sponge Siphonochalina si-phonella: S. Carmely & Y. Kashman; J. Org. Chem. 48, 3517 (1983) New triterpenoids from the Red Sea sponge Siphonochalina siphonella: Y. Kashman, et al.; J. Nat. Prod. 64, 175 (2001) Reversal of P-glycoprotein-mediated multidrug resistance by Sipholane triterpenoids: S. Jain, et al.; J. Nat. Prod. 70, 928 (2007) Sipholenol A, a marine-derived sipholane triterpene, potently reverses P-glycoprotein (ABCB1)-mediated multidrug resistance in cancer cells: Z. Shi, et al.; Cancer Sci. 98, 1373 (2007) Biocatalysis of the anticancer sipholane triterpenoids: S. Jain, et al.; Planta Med. 73, 591 (2007)

Product Activity Prod. No. Size

Mensacarcin Cytotoxic ALX-380-131-M001ALX-380-131-M005

1 mg5 mg

MM 47755 Anti-fungalAnti-bacterial

ALX-380-128-M001ALX-380-128-M005

1 mg5 mg

Naphthomycin B Anti-fungalAnti-bacterial

ALX-380-129-M001 1 mg

Obscurolide A1 PDE inhibitor (weak) ALX-350-165-M001ALX-350-165-M005

1 mg5 mg

Polyketomycin[Antibiotic K99-5147]

Anti-bacterialAnti-tumor

ALX-380-127-M001 1 mg

Psicofuranine[Angustmycin C]

Xanthosine monophosphate aminase inhibitor, Anti-tumor

ALX-380-138-M001ALX-380-138-M005

1 mg5 mg

Purmorphamine Hedgehog activatorOsteoclast differentiator

ALX-420-045-M001ALX-420-045-M005ALX-420-045-M025

1 mg5 mg

25 mg

Reductiomycin Anti-bacterial, Anti-fungalAnti-viral, Anti-tumor

ALX-380-136-M001ALX-380-136-M005

1 mg5 mg

Sarcophine ATPase & AChE inhibitor, Anti-tumor ALX-350-166-M002ALX-350-166-M010

2 mg10 mg

Sertraline . HCl Anti-proliferative (colon cancer) BML-NS115-0010BML-NS115-0050

10 mg50 mg

Swinholide A Cytotoxic, Cytoskeleton disruption ALX-350-088-C010ALX-350-088-C050

10 μg50 μg

Territrem B Mycotoxin, AChE inhibitor ALX-630-117-MC05ALX-630-117-M001

0.5 mg1 mg

Sipholenone A

Sipholenone A

Just Released

NAT

UR

AL

PR

OD

UCT

S &

RA

RE

AN

TIB

IOTI

CS


12A

NTI

BO

DIE

S

Antibodies BAG-3 - Downregulates Apoptosis

BAG-3 (Bcl-2-binding Athanogene-3; Docking Protein CAIR-1) participates in a wide variety of cellular processes includ-ing signaling, transcription, stress response and apoptosis. It forms a complex with HSC70 and assists in polypeptide folding.

LIT: Bag3 gene expression is regulated by heat shock factor 1: S. Franceschelli, et al.; J. Cell Physiol. 215, 575 (2008).

MAb to BAG-3 (AC-1)ALX-803-323-C100 100 μgCLONE: AC-1. ISOTYPE: Mouse IgG1. IMMUNOGEN: Synthetic peptide corre-sponding to aa 18-33 (D18RDPLPPGWEIKIDPQ33) of N-terminal human BAG-3 (Bcl-2-binding athanogene-3). SPECIFICITY: Recognizes human, mouse and rat BAG-3. APPLICATION: ELISA, IHC, ICC, IP, WB.LIT: Bag3 gene expression is regulated by heat shock factor 1: S. Franceschelli, et al.; J. Cell Physiol. 215, 575 (2008)

RhoBTB2 (DBC2) - A New Player in Apoptosis

RhoBTB2 (DBC2) is a mitotic E2F1 target gene with a novel role in apoptosis.

LIT: RhoBTB2 (DBC2) is a mitotic E2F1 target gene with a novel role in apoptosis: S.N. Freeman, et al.; J. Biol. Chem. 283, 2353 (2008)

PAb to Rho-related BTB Domain-containing Protein 2ALX-215-062-C050 50 μgFrom rabbit. IMMUNOGEN: Synthetic peptide corresponding to the conserved human Rho-related BTB domain-containing protein 2 amino acids 673-687 (KEEDHYQRARKEREK) with an N-terminal C-residue. SPECIFICITY: Recog-nizes human, mouse, rat, chicken and zebrafish Rho-related BTB domain-containing protein 2. APPLICATION: ICC, WB.LIT: RhoBTB2 (DBC2) is a mitotic E2F1 target gene with a novel role in apoptosis: S.N. Freeman, et al.; J. Biol. Chem. 283, 2353 (2008)

TIGAR – No Threat to Die

TIGAR (TP53-induced glycolysis and apoptosis regulator) has been identifi ed as a novel p53-inducible gene. TIGAR expres-sion decreased fructose-2,6-bisphosphate levels in cells, re-sulting in an inhibition of glycolysis. In addition, TIGAR expres-sion lowered intracellular reactive oxygen species (ROS) levels and protected cells from p53-induced apoptosis.

LIT: TIGAR, a p53-inducible regulator of glycolysis and apoptosis: K. Bensaad, et al.; Cell 126, 107 (2006).

PAb to TIGAR (AT122)ALX-210-947-C100 100 μgFrom rabbit. IMMUNOGEN: Recombinant human TIGAR (aa 1-270) fused at the N-terminus to a tag. SPECIFICITY: Recognizes human and mouse TIGAR. APPLICATION: WB.

MAb to TIGAR (human) (Woody-1)ALX-804-872-C100 100 μgCLONE: Woody-1. ISOTYPE: Mouse IgG2b. IMMUNOGEN: Recombinant human TIGAR (aa 1-270). SPECIFICITY: Recognizes human TIGAR. APPLICATION: IP, WB.

Lamin A - NEW Risk Biomarker for Colorectal Cancer

Lamin A is a type V intermediate fi lament protein. Mutations in lamin A are associated with several genetic degenerative diseases, including Hutchinson-Gilford progeria syndrome (HGPS), which is caused by progerin, a truncated version of lamin A. Recently, A-type lamins were described as novel prognostic biomarkers for colorectal cancer.

LIT: The mutant form of lamin A that causes Hutchinson-Gilford progeria is a biomarker of cellular aging in human skin: D. McClintock, et al.; PLoS ONE 2, e1269 (2007) Lamin A/C is a risk bi-omarker in colorectal cancer: N.D. Willis, et al.; PLoS ONE 3, e2988 (2008)

MAb to Lamin A/C (4C11)ALX-804-672-C200 200 μgCLONE: 4C11. ISOTYPE: Mouse IgG2a. IMMUNOGEN: Recombinant human lam-in A/C (aa 430-545). SPECIFICITY: Recognizes human, mouse, rat, hamster and monkey lamin A/C. Cross-reacts with lamin B1 and lamin B2. APPLI-CATION: ICC, IP, WB.

MAb to Progerin (human) (13A4)ALX-804-662-R200 200 μlCLONE: 13A4. ISOTYPE: Mouse IgG1. IMMUNOGEN: Synthetic KLH-coupled peptide corresponding to aa 604-611 (G604AQSPQNC611) at the C-terminus of human progerin. SPECIFICITY: Recognizes human progerin. Does not cross-react with endogenous prelamin A. APPLICATION: ICC, IP, WB.

TGF-βRIII & Tumorigenesis

TGF-β receptor III (TGF-βRIII; betaglycan) is an ubiquitously expressed transmembrane proteoglycan TGF-β co-receptor that regulates TGF-β signaling by increasing the binding of TGF-β to the subunit II of TGF-β receptor. The overexpres-sion of TGF-β receptor III in breast cancer cells suppresses their tumorigenicity in an animal model.

LIT: The type III transforming growth factor-beta receptor as a novel tumor suppressor gene in pros-tate cancer: R.S. Turley, et al.; Cancer Res 67, 1090 (2007) Expression of the type III TGF-beta receptor is negatively regulated by TGF-beta: N. Hempel, et al.; Carcinogenesis 29, 905 (2008)

MAb to TGF-βRIII (human) (Jack-1)ALX-804-871-C100 100 μgCLONE: Jack-1. ISOTYPE: Mouse IgG2b. IMMUNOGEN: Recombinant human TGF-βRIII cytoplasmic domain (aa 809-850). SPECIFICITY: Recognizes hu-man TGF-βRIII. APPLICATION: IP, WB.

FIGURE: Immunocytochemical staining of HeLa cells with MAb to Lamin A/C (4C11) (Prod. No. ALX-804-672). DNA was counterstained with Hoechst 33342.

incorporating



13

AN

TIB

OD

IES

NKT Cell Ligands

Latest AdditionsProduct Source/

IsotypeSpecificity Application Prod. No. Size

MAb to APRIL (human) (Aprily-5) Mouse IgG1 Human IP, WB, ELISA ALX-804-801-C100 100 μg

MAb to BCMA (mouse) (Vicky-2) Rat IgG2a Mouse IP, FC, WB, Blocking ALX-804-826-C100 100 μg

MAb to CD137 (mouse) (M4202) Rat IgG1 Mouse FC, WB ALX-804-747-C050 50 μg

PAb to CD137 (mouse) From rat Mouse FC, WB ALX-210-489-C100 100 μg

MAb to CD137L (human) (41B446) Mouse IgG1 Human FC, WB ALX-804-748-C050 50 μg

PAb to DPR1 From rabbit Human, mouse WB, ICC, IP ALX-215-059-C100 100 μg

MAb to FGF-19 (human) (FG369-1) Mouse IgG1 Human ELISA, WB ALX-804-751-C050ALX-804-751-C100

50 μg100 μg

MAb to FGF-19 (human) (FG98-6) Mouse IgG2b Human ELISA, WB ALX-804-750-C050ALX-804-750-C100

50 μg100 μg

MAb to FGF-21 (human) (FG204-3) Mouse IgG2b Human ELISA, WB ALX-804-752-C050ALX-804-752-C100

50 μg100 μg

MAb to FGF-21 (human) (FG348-1) Mouse IgG1 Human ELISA, WB ALX-804-753-C050ALX-804-753-C100

50 μg100 μg

MAb to LRRC32 (Plato-1) Mouse IgG2b Human, mouse FC, IP, WB ALX-804-867-C100 100 μg

PAb to NALP12 (mouse) (AT141) From rabbit Mouse WB ALX-210-967-C100 100 μg

MAb to Tollip (Kimmy-2) Mouse IgG1 Human, mouse ICC, IP, WB ALX-804-154-C100 100 μg

KRN7000[α-Gal-Cer; α-Galactosylceramide]

BML-SL232-0100 100 μgBML-SL232-1000 1 mgPotent stimulator of natural killer T (NKT) cells. Originally isolated from the marine sponge Agelas mauritianus.LIT: Syntheses of alpha-, beta-monoglycosylceramides and four diasteromers of an alpha-galactosylceramide: M. Morita, et al.; Bioorg. Med. Chem. Lett. 5, 699 (1995) Synthesis and biologi-cal evaluation of alpha-galactosylceramide (KRN7000) and isoglo-botrihexosylceramide (iGb3): C. Xia, et al.; Bioorg. Med. Chem. Lett. 16, 2195 (2006)

Isoglobotrihexosylceramide[iGb3]

ALX-306-028-C100 100 μg ALX-306-028-M001 1 mgLysosomal glycosphingolipid proposed to be the natural ligand of NKT cells. Stimulates natural killer T (NKT) cells similar to α-Gal-Cer.LIT: Lysosomal glycosphingolipid recognition by NKT cells: D. Zhou, et al.; Science 306, 1786 (2004) Synthesis and biological evaluation of alpha-galactosylcera-mide (KRN7000) and isoglobotrihex-osylceramide (iGb3): C. Xia, et al.; Bioorg. Med. Chem. Lett. 16, 2195 (2006) Chemoenzymatic Syntheses of iGb3 and Gb3: Q. Yao et al.; Org. Lett. 8, 911 (2006)

OCH ALX-306-029-C250 250 μgALX-306-029-M001 1 mgTruncated analog of α-Gal-Cer. Selectively induces IL-4, as opposed to IFN-γ. Stimulation of NKT cells with OCH results in release of primarily Th2 cytokine.LIT: Synthesis and evaluation of sphinganine analogues of KRN7000 and OCH: R.M. Ndonye, et al.; J. Org. Chem. 70, 10260 (2005) Total synthesis of an immunosuppressive glycoli-pid, (2S,3S,4R)-1-O- (alpha-d-galactosyl)-2- tetracosanoylamino-1,3,4-nonanetriol: K. Murata, et al.; J. Org. Chem. 70, 2398 (2005) Glycolipids for natural killer T cells: P.B. Savage, et al.; Chem.

Soc. Rev. 351, 771 (2006)

α-Mannosyl Ceramide [α-ManCer]

ALX-306-031-C250 250 μg ALX-306-031-M001 1 mgPotent stimulator of natural killer T (NKT) cells expressing the invariant Vα19-Jα26 T cell receptor α chain (Vα19 NKT cells).LIT: Synthetic alpha-mannosyl ceramide as a potent stimulant for an NKT cell repertoire bearing the invariant Valpha19-Jal-pha26 TCR alpha chain: N. Okamoto, et al.; Chem. Biol. 12, 677 (2005) Induction of promotive rather than suppressive immune responses from a novel NKT cell repertoire Valpha19 NKT cell with alpha-mannosyl ceramide analogues consisting of the immunosuppressant ISP-I as the sphingosine unit: M. Shimamura, et al.; Eur. J. Med. Chem. 41, 569 (2006)


14

Ubiquitin Research – Linkage-specifi c ReagentsUbiquitin Chains

Product Prod. No. Size

Di-ubiquitin (Ub2) (K48-linked) BML-UW9800-0100 100 μg

Tetra-ubiquitin (Ub4) (K48-linked) BML-UW8645-0025 25 μg

Multi Ubiquitin Chains (Ub2-7) (K48-linked) BML-UW8860-0100 100 μg

Tetra-ubiquitin (Ub4) (K63-linked) BML-UW0715-0025 25 μg

Multi Ubiquitin Chains (Ub2-7) (K63-linked) BML-UW9570-0100 100 μg

New Polyubiquitin (K63-linkage-specific) Antibody

Modifi cation of proteins by addition of K63-linked polyubiqui-tin chains is implicated in a variety of cellular events, includ-ing DNA repair, signal transduction and receptor endocyto-sis. Enzo Life Sciences now introduces a new monoclonal antibody that specifi cally recognizes K63-linked polyubiquitin, but NOT any other isopeptide-linked (K6, K11, K27, K29, K33, or K48) polyubiquitinylated species. This unique monoclonal an-tibody is a powerful tool facilitating the analysis of K63-linked polyubiquitinylation.

FIGURE: A. Immunodetection by western blot following SDS-PAGE of polyubiquitin chains using BML-PW0600 [clone HWA4C4], peroxidase-labelled secondary antibody, and subsequent development using chemiluminescence. B. Formalin-fixed paraffin-embedded sections of hippocampus from human Alzheimer’s disease brain stained with BML-PW0600 at 1:100 dilution, with biotinylated secondary antibody and DAB detection.

Product Source/Isotype Specificity Application Prod. No. Size

MAb to Polyubiquitin (K63-linkage-specific) (HWA4C4)

From rabbit Wide range of species ELISA, IHC, WB BML-PW0600-0025

BML-PW0600-0100

25 μl100 μl

MAb to Polyubiquitin (K63-linkage-specific) (HWA4C4) (HRP)

From rabbit Wide range of species WB BML-PW0605-0025

BML-PW0605-0100

25 μl100 μl

A B


(Ubn)-ubiquitinylated Substrate BML-UW0610-0025 25 μg

([K6-only]Ubn)-ubiquitinylated Substrate BML-UW0615-0025 25 μg







Ubiquitin Modified Conjugates

Enzo Life Sciences offers a new range of ubiquitin modifi ed conjugates that may be of utility for probing the linkage-type specifi city of polyubiquitin-interacting proteins or complex-es, such as ubiquitin binding domains/proteins or deubi-

quitinylating enzymes (DUBs). These single isopeptide link-age-based conjugates are prepared using single lysine only mutant ubiquitins. The conjugates has been characterized by SDS-PAGE, western blotting and mass spectrometry.

FIGURE: West-ern blot following SDS-PAGE of sin-gle lysine mutant chains probed with polyubiquitin chain-reactive mouse mAb FK1 (BML-PW8805).

UBIQ

UITI

N RE

SEAR

CH

incorporating



15

Tools for SUMO Research Latest AdditionsSUMOylation Kit

Protein Derivatives

Antibodies

Mutants

The kit provides a means of generating SUMOylated pro-teins in vitro, by covalent linkage of the carboxy-terminal of SUMO-1, -2 or -3 to specifi c lysine residues on a target pro-tein. A control target protein is provided together with all

other necessary components. SUMO specifi c antibodies are included in the kit for detection of SUMOylated proteins via SDS-PAGE and western blotting. Provides suffi cient material for 20 x 20 μl reactions.


SUMOylation Kit BML-UW8955-0001 1 Kit

These SUMO derivatives are biotinylated via one or more of SUMO’s eleven internal lysine residues, thereby providing a potential route to affi nity purifi cation of subsequently con-

jugated substrates (or thioester-linked enzymes) on avidin/streptavidin matrices.

New sheep polyclonal antibodies, characterized for specifi ci-ty against the appropriate SUMO family member and its cor-

responding conjugates. Complementing an existing range of rabbit pAbs. Suitable for use in WB, ICC and IP.


SUMO-1 (human) (rec.) (biotinylated) BML-UW0545-0100 100 μg




(K11R)SUMO-2 (human) (rec.) (GST) BML-UW0380-0100 100 μg

(K11R)SUMO-3 (human) (rec.) (GST) BML-UW0385-0100 100 μg

(K11R)SUMO-2 (human) (rec.) BML-UW0515-0100 100 μg

(K11R)SUMO-3 (human) (rec.) BML-UW0520-0100 100 μg

Product Source/Isotype Specificity Application Prod. No. Size

PAb to SUMO-1 From sheep Human IHC, IP, WB BML-PW0505-0025BML-PW0505-0100

25 μl100 μl

PAb to SUMO-2 From sheep Human. Cross-reacts with SUMO-3

IHC, IP, WB BML-PW0510-0025BML-PW0510-0100

25 μl100 μl

New (K11R) SUMO2/3 mutants that are incapable of forming polySUMO chains at Lys11 and can be used to selectively mono-/multi-SUMOylate target proteins.

Deconjugating Enzyme (DCEs) Substrates

Synthetic substrates that may prove of utility in assessing the hydrolytic activity of deSUMOylating enzymes.


SUMO-1 (93-97)-AMCA Peptide BML-UW0500-1000 1 mg

SUMO-1-AMC BML-UW0040-0025 25 μg

SUMO-2-AMC BML-UW0045-0025 25 μg

TOO

LS F

OR

SUM

O R

ESEA

RCH

Cellular Analysis

Isolation of Ubiquitinylated Proteins

GFP-Certified™ Apoptosis/Necrosis Detection SystemENZ-51002-25 25 Reactions ENZ-51002-100 100 Reactions The GFP-Certifi ed™ Apoptosis/Necrosis Detec-tion System was specifi cally designed for use with GFP-expressing cell lines and cells expressing blue or cyan fl uorescent proteins (BFPs, CFPs). It includes all the necessary reagents for determina-tion of early and late stages of apoptosis as well as necrosis. The kit is suitable for use with live or post-fi xed cells in conjunction with probes, such as labeled antibodies, or other fl uorescent con-jugates displaying similar spectral properties as fl uorescein or coumarin. Additionally, it provides quick and accurate results via fl ow cytometry and fl uorescence/confocal microscopy.

FIGURE: GFP-expressing cell line stained with GFP-Certified™ Apoptosis/Necrosis Detection SystemA: Viable cells C: Late apoptotic cellsB: Early apoptotic cells D: Necrotic cells

FIGURE: U2OS cells stained with Total-Nuclear-ID™ demonstrates staining for the nucleus (red) and nucleolus (yellowish-green).

Product Prod. No.

GFP-Certified™ Lyso-ID™ Red Lysosomal Detection Kit

ENZ-51005

GFP-Certified™ Mito-ID™ Red Mitochondrial Detection Kit

ENZ-51007

Total Nuclear-ID™ Green/Red Nucleolar/Nuclear Detection Kit

ENZ-51006

Related Organelle Profiling Tools

The UbiQapture™-Q Kit is an effi cient tool for the selective isolation of ubiquitinylated pro-teins. The Kit facilitates the isolation of mono-,multi- and poly-ubiquitinylated proteins (be-lieved to be independent of lysine residue chain linkage) from cell extracts, tissue lysates and in vitro assay solutions through use of a high-binding affi nity matrix. Provides suffi cient material for approximately 25 binding assays.

Possible utility:

1. Isolation and detection of ubiquitinylated protein conjugates from a specifi c cell/tis-sue lysate.

2. Capture and analysis of specifi c ubiquiti-nylated protein conjugates of interest from particular cell/tissue lysates.

3. Separation of ubiquitinylated/non-ubiquiti-nylated forms of specifi c proteins of inter-est.

4. Release of free proteins in their active/native form by cleavage of bound ubiquitin chains from the UbiQapture™-Q matrix using a deubiquitinylating enzyme.

5. Release of ubiquitinylated proteins in their active/native form by elution from the UbiQapture™-Q matrix using high salt buffer.


UbiQapture™-Q Kit BML-UW8995-0001 1 Kit

D

C

B

A

incorporating


Switzerland & Rest of EuropeENZO LIFE SCIENCES AG Industriestrasse 17, PostfachCH-4415 Lausen / SwitzerlandTel. + 41/0 61 926 89 89Fax + 41/0 61 926 89 [email protected]

North/South AmericaENZO LIFE SCIENCES INTERNATIONAL, INC.5120 Butler PikePlymouth Meeting, PA 19462-1202USATel. 1-800-942-0430 / (610) 941-0430Fax (610) [email protected]

BeneluxENZO LIFE SCIENCES BVBAMelkerijweg 3BE-2240 Zandhoven / BelgiumTel. +32/0 3 466 04 20 Fax +32/0 3 466 04 [email protected]

GermanyENZO LIFE SCIENCES GmbHMarie-Curie-Strasse 8DE-79539 Lörrach / GermanyTel. +49/0 7621 5500 526Toll Free: 0800 6649518Fax +49/0 7621 5500 [email protected]

UK & IrelandENZO LIFE SCIENCES (UK) LTD.Palatine House Matford CourtExeter EX2 8NL / UKTel. 0845 601 1488 (UK customers)Tel. +44/0 1392 825900 (overseas)Fax +44/0 1392 [email protected]

For Local Distributors please visit our Website.

cancer, immunology & cell death · mab to trail (human) (hs501) alx-804-300-c100 100 μg pab to...

Documents